A citation-based method for searching scientific literature

Sooryanarayana Varambally, Saravana M Dhanasekaran, Ming Zhou, Terrence R Barrette, Chandan Kumar-Sinha, Martin G Sanda, Debashis Ghosh, Kenneth J Pienta, Richard G A B Sewalt, Arie P Otte, Mark A Rubin, Arul M Chinnaiyan. Nature 2002
Times Cited: 1963







List of co-cited articles
1107 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Targeting EZH2 in cancer.
Kimberly H Kim, Charles W M Roberts. Nat Med 2016
798
27

The Polycomb complex PRC2 and its mark in life.
Raphaël Margueron, Danny Reinberg. Nature 2011
23

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.
Celina G Kleer, Qi Cao, Sooryanarayana Varambally, Ronglai Shen, Ichiro Ota, Scott A Tomlins, Debashis Ghosh, Richard G A B Sewalt, Arie P Otte, Daniel F Hayes,[...]. Proc Natl Acad Sci U S A 2003
22

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.
Kexin Xu, Zhenhua Jeremy Wu, Anna C Groner, Housheng Hansen He, Changmeng Cai, Rosina T Lis, Xiaoqiu Wu, Edward C Stack, Massimo Loda, Tao Liu,[...]. Science 2012
556
17

EZH2: a novel target for cancer treatment.
Ran Duan, Wenfang Du, Weijian Guo. J Hematol Oncol 2020
150
17

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
Michael T McCabe, Heidi M Ott, Gopinath Ganji, Susan Korenchuk, Christine Thompson, Glenn S Van Aller, Yan Liu, Alan P Graves, Anthony Della Pietra, Elsie Diaz,[...]. Nature 2012
16

Role of histone H3 lysine 27 methylation in Polycomb-group silencing.
Ru Cao, Liangjun Wang, Hengbin Wang, Li Xia, Hediye Erdjument-Bromage, Paul Tempst, Richard S Jones, Yi Zhang. Science 2002
16

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
14

Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
Sarah K Knutson, Satoshi Kawano, Yukinori Minoshima, Natalie M Warholic, Kuan-Chun Huang, Yonghong Xiao, Tadashi Kadowaki, Mai Uesugi, Galina Kuznetsov, Namita Kumar,[...]. Mol Cancer Ther 2014
367
13

Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Jeffrey A Simon, Carol A Lange. Mutat Res 2008
621
13

EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Adrian P Bracken, Diego Pasini, Maria Capra, Elena Prosperini, Elena Colli, Kristian Helin. EMBO J 2003
897
12


EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
Ingeborg M Bachmann, Ole J Halvorsen, Karin Collett, Ingunn M Stefansson, Oddbjørn Straume, Svein A Haukaas, Helga B Salvesen, Arie P Otte, Lars A Akslen. J Clin Oncol 2006
598
11

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Antoine Italiano, Jean-Charles Soria, Maud Toulmonde, Jean-Marie Michot, Carlo Lucchesi, Andrea Varga, Jean-Michel Coindre, Stephen J Blakemore, Alicia Clawson, Benjamin Suttle,[...]. Lancet Oncol 2018
323
10

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.
Sarah K Knutson, Natalie M Warholic, Tim J Wigle, Christine R Klaus, Christina J Allain, Alejandra Raimondi, Margaret Porter Scott, Richard Chesworth, Mikel P Moyer, Robert A Copeland,[...]. Proc Natl Acad Sci U S A 2013
487
10

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
Ryan D Morin, Nathalie A Johnson, Tesa M Severson, Andrew J Mungall, Jianghong An, Rodrigo Goya, Jessica E Paul, Merrill Boyle, Bruce W Woolcock, Florian Kuchenbauer,[...]. Nat Genet 2010
10

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
10

SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Kimberly H Kim, Woojin Kim, Thomas P Howard, Francisca Vazquez, Aviad Tsherniak, Jennifer N Wu, Weishan Wang, Jeffrey R Haswell, Loren D Walensky, William C Hahn,[...]. Nat Med 2015
261
9

Regulation of chromatin by histone modifications.
Andrew J Bannister, Tony Kouzarides. Cell Res 2011
9

The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.
Daniel Zingg, Julien Debbache, Simon M Schaefer, Eylul Tuncer, Sandra C Frommel, Phil Cheng, Natalia Arenas-Ramirez, Jessica Haeusel, Yudong Zhang, Mario Bonalli,[...]. Nat Commun 2015
217
9

Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
Jung Kim, Yongik Lee, Xiaodong Lu, Bing Song, Ka-Wing Fong, Qi Cao, Jonathan D Licht, Jonathan C Zhao, Jindan Yu. Cell Rep 2018
115
9

Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.
Eunhee Kim, Misuk Kim, Dong-Hun Woo, Yongjae Shin, Jihye Shin, Nakho Chang, Young Taek Oh, Hong Kim, Jingeun Rheey, Ichiro Nakano,[...]. Cancer Cell 2013
507
9

Targeting EZH2 in cancer therapy.
Makoto Yamagishi, Kaoru Uchimaru. Curr Opin Oncol 2017
125
8

Histone Modifications and Cancer.
James E Audia, Robert M Campbell. Cold Spring Harb Perspect Biol 2016
324
8

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.
Lu Gan, Yanan Yang, Qian Li, Yi Feng, Tianshu Liu, Weijian Guo. Biomark Res 2018
168
8

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
8

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
Michael T McCabe, Alan P Graves, Gopinath Ganji, Elsie Diaz, Wendy S Halsey, Yong Jiang, Kimberly N Smitheman, Heidi M Ott, Melissa B Pappalardi, Kimberly E Allen,[...]. Proc Natl Acad Sci U S A 2012
332
8

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Sarah K Knutson, Tim J Wigle, Natalie M Warholic, Christopher J Sneeringer, Christina J Allain, Christine R Klaus, Joelle D Sacks, Alejandra Raimondi, Christina R Majer, Jeffrey Song,[...]. Nat Chem Biol 2012
568
8

Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.
Bin Shi, Jing Liang, Xiaohan Yang, Yan Wang, Youna Zhao, Huijian Wu, Luyang Sun, Ying Zhang, Yupeng Chen, Ruifang Li,[...]. Mol Cell Biol 2007
244
8

Regulation and Role of EZH2 in Cancer.
Hirohito Yamaguchi, Mien-Chie Hung. Cancer Res Treat 2014
184
8

EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells.
Shuo Huang, Zhongyu Wang, Jie Zhou, Jiani Huang, Li Zhou, Jing Luo, Yisong Y Wan, Haixia Long, Bo Zhu. Cancer Res 2019
71
9

Writing, erasing and reading histone lysine methylations.
Kwangbeom Hyun, Jongcheol Jeon, Kihyun Park, Jaehoon Kim. Exp Mol Med 2017
444
7

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
Jindan Yu, Jianjun Yu, Ram-Shankar Mani, Qi Cao, Chad J Brenner, Xuhong Cao, Xiaoju Wang, Longtao Wu, James Li, Ming Hu,[...]. Cancer Cell 2010
610
7

N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Etienne Dardenne, Himisha Beltran, Matteo Benelli, Kaitlyn Gayvert, Adeline Berger, Loredana Puca, Joanna Cyrta, Andrea Sboner, Zohal Noorzad, Theresa MacDonald,[...]. Cancer Cell 2016
279
7

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.
Timothy A Yap, Jane N Winter, Lisa Giulino-Roth, Jemma Longley, Juanita Lopez, Jean-Marie Michot, John P Leonard, Vincent Ribrag, Michael T McCabe, Caretha L Creasy,[...]. Clin Cancer Res 2019
67
10

An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
Kyle D Konze, Anqi Ma, Fengling Li, Dalia Barsyte-Lovejoy, Trevor Parton, Christopher J Macnevin, Feng Liu, Cen Gao, Xi-Ping Huang, Ekaterina Kuznetsova,[...]. ACS Chem Biol 2013
304
7


An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Wei Qi, Kehao Zhao, Justin Gu, Ying Huang, Youzhen Wang, Hailong Zhang, Man Zhang, Jeff Zhang, Zhengtian Yu, Ling Li,[...]. Nat Chem Biol 2017
183
7

Maintaining cell identity: PRC2-mediated regulation of transcription and cancer.
Itys Comet, Eva M Riising, Benjamin Leblanc, Kristian Helin. Nat Rev Cancer 2016
257
7

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Benjamin G Bitler, Katherine M Aird, Azat Garipov, Hua Li, Michael Amatangelo, Andrew V Kossenkov, David C Schultz, Qin Liu, Ie-Ming Shih, Jose R Conejo-Garcia,[...]. Nat Med 2015
406
7

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
6

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.
Christopher J Sneeringer, Margaret Porter Scott, Kevin W Kuntz, Sarah K Knutson, Roy M Pollock, Victoria M Richon, Robert A Copeland. Proc Natl Acad Sci U S A 2010
467
6

Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites.
Birgit Czermin, Raffaella Melfi, Donna McCabe, Volker Seitz, Axel Imhof, Vincenzo Pirrotta. Cell 2002
6

A687V EZH2 is a gain-of-function mutation found in lymphoma patients.
Christina R Majer, Lei Jin, Margaret Porter Scott, Sarah K Knutson, Kevin W Kuntz, Heike Keilhack, Jesse J Smith, Mikel P Moyer, Victoria M Richon, Robert A Copeland,[...]. FEBS Lett 2012
109
6

Discovery of a first-in-class EZH2 selective degrader.
Anqi Ma, Elias Stratikopoulos, Kwang-Su Park, Jieli Wei, Tiphaine C Martin, Xiaobao Yang, Megan Schwarz, Violetta Leshchenko, Alexander Rialdi, Brandon Dale,[...]. Nat Chem Biol 2020
75
8

Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers.
Shuet Theng Lee, Zhimei Li, Zhenlong Wu, Meiyee Aau, Peiyong Guan, R K Murthy Karuturi, Yih Cherng Liou, Qiang Yu. Mol Cell 2011
267
6


DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.
Tina Branscombe Miranda, Connie C Cortez, Christine B Yoo, Gangning Liang, Masanobu Abe, Theresa K Kelly, Victor E Marquez, Peter A Jones. Mol Cancer Ther 2009
416
6

Integrative genomic profiling of human prostate cancer.
Barry S Taylor, Nikolaus Schultz, Haley Hieronymus, Anuradha Gopalan, Yonghong Xiao, Brett S Carver, Vivek K Arora, Poorvi Kaushik, Ethan Cerami, Boris Reva,[...]. Cancer Cell 2010
6

Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein.
Andrei Kuzmichev, Kenichi Nishioka, Hediye Erdjument-Bromage, Paul Tempst, Danny Reinberg. Genes Dev 2002
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.